Nano-X Imaging Ltd. Stock Price, News & Analysis

Nanox (Nasdaq: NNOX) announced a distribution collaboration with Althea France to introduce the CE-marked Nanox.ARC multi-source digital tomosynthesis system across France.

Althea France, part of the Althea Group that manages thousands of imaging devices, will lead market introduction, sales and service and leverage relationships with university hospitals, public hospitals and private clinics. This deal is Nanox's fourth European distribution agreement following partnerships in Greece, Romania and the Czech Republic. The Nanox.ARC is cleared for commercialization across the European Union following CE Mark certification.

Nanox (Nasdaq: NNOX) announced that its deep‑learning subsidiary Nanox.AI had two bone‑analysis tools — HealthVCF and the upgraded HealthOST — recommended by NICE for inclusion in an Early Value Assessment in UK NHS hospitals for a three‑year evidence‑generation period beginning November 24, 2025.

The tools will be assessed for their ability to support opportunistic detection of vertebral fragility fractures on X‑rays and CT scans, be compared with current NHS standard of care, and are eligible for core NHS funding while evidence is gathered. Two of five AI bone solutions in the assessment are from Nanox.AI.

Nanox (Nasdaq: NNOX) announced a registered direct offering of 3,826,530 ordinary shares expected to raise gross proceeds of approximately $15 million before offering expenses. The closing is expected on or about November 25, 2025, subject to customary closing conditions. The company said it intends to use net proceeds for working capital and general corporate purposes. Titan Partners Group is acting as sole placement agent. The offering is made under an effective Form F-3 shelf registration that became effective May 5, 2023, and will be described in a prospectus supplement filed with the SEC.

Nanox (NASDAQ:NNOX) reported third-quarter 2025 results and a business update on November 20, 2025. The company generated $3.4M revenue in Q3 2025 versus $3.0M year-ago, and reported a GAAP net loss of $13.7M for the quarter. Gross loss was $2.9M (GAAP) and non-GAAP gross loss was $0.3M. Nanox completed the acquisition of Vaso Healthcare IT, added clinical sites including Cedars-Sinai and Olympe Imagerie, and signed European ARC distribution partnerships. Cash and equivalents totaled $55.5M as of September 30, 2025, and the company expects >100 deployed units by year-end 2025 and $35M revenue for 2026.

Nanox (Nasdaq: NNOX) agreed to acquire VasoHealthcare IT Inc. from Vaso (OTCQX: VASO) to accelerate U.S. deployment of its AI imaging solutions. The transaction is expected to close within a couple of weeks and integrates VHC IT’s implementation, systems integration, workflow optimization, data migration, user training, and nationwide go-live support with Nanox.AI’s FDA-cleared CT-scan AI tools.

Consideration is up to $800,000: $200,000 cash at closing plus up to $600,000 in performance-based earnouts over two years contingent on revenue retention of existing customers.

Nanox (NASDAQ: NNOX) announced a collaboration with Paris-based radiology group Olympe Imagerie to deploy the Nanox.ARC at Hospital Privé Jacques Cartier MASSY for lung cancer screening clinical trials, dated Nov 14, 2025. The Nanox.ARC, a multi-source digital tomosynthesis system, received its CE Mark in February 2025 and is cleared for commercialization across the EU. The deployment advances Nanox’s European clinical validation program and commercial presence. Olympe Imagerie’s centers collectively serve more than 400,000 outpatients, inpatients, and visitors annually, offering significant clinical exposure for trial activities.

Nanox (Nasdaq: NNOX) will launch and demonstrate the FDA 510(k)-cleared Nanox.ARC X multi-source digital tomosynthesis system at RSNA 2025 (Nov 30–Dec 4, 2025) in Chicago. The Nanox.ARC X received FDA clearance in April 2025 for musculoskeletal, pulmonary, intra-abdominal and paranasal indications and is described as lower cost and lower radiation than CT. Live demos run every 30 minutes at Booth #3914. The company will also present clinical data, unveil a pulmonary nodule AI under development, and introduce two new AI tools for aortic valve calcification and body composition measurement.

Nanox (Nasdaq: NNOX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 20, 2025 before market open. Management will host a conference call and live webcast on the same day at 8:30 a.m. ET to review results and provide a business update. Registration and the live webcast will be available via the company website in the Investor Relations Events and Presentations section.

NANO-X IMAGING (Nasdaq: NNOX) on November 6, 2025 announced a distribution agreement with Czech imaging distributor EXRAY to introduce the Nanox.ARC multi-source digital tomosynthesis system across the Czech Republic.

EXRAY, founded in 2013, has installations in >50% of the country’s ~200 healthcare facilities and will lead market introduction, sales and service. The Nanox.ARC holds a CE Mark clearance for commercialization across the European Union.